So Vance, let's get to your word of the day. Your word of the day today is productive. And I was trying to figure out what could this be alluding to because we got a government shutdown going on.Uh we're still a couple days away from earning season. What what productivity are you seeing. >> Uh we got to stay positive, Frank.Man, don't think about all these negative things. And by the way, government shutdowns never work. They're just a they're just they're a comical joke anymore.We've been having government ...

Core Insights - The current market is experiencing volatility due to a government shutdown, impacting futures and investor sentiment [1] - The artificial intelligence boom is driving the tech-heavy Nasdaq towards all-time highs, with a focus on stock selection and profit-taking strategies [1] Group 1: Stock Analysis - The IBD Breakout Stocks Index highlights stocks like Charles Schwab (SCHW), Hims & Hers Health (HIMS), and CrowdStrike (CRWD) as key players to watch [2] - Emcor (EME) is noted for its AI infrastructure role, currently forming a second-stage flat base with a buy point of 667.64 [3] - CrowdStrike is targeting a buy point of 507.20 in a cup with handle formation, showing strong technical indicators [4] Group 2: Market Trends - AppLovin (APP) and Alphabet (GOOGL) are extended beyond their buy ranges, indicating strong market performance [5] - TE Connectivity (TEL) is recognized for its connections in AI infrastructure and is trading within buy range after clearing a buy point of 212.76 [7] - The IBD Breakout Opportunities ETF (BOUT) allows investors to gain exposure to the entire index, providing a diversified investment option [10]

CHONGQING, CHINA - MAY 04: In this photo illustration, the logo of Hims & Hers Health, Inc. is displayed on a smartphone screen, with the company's stock market performance and candlestick chart visible in the background, on May 4, 2025, in Chongqing, China. Hims & Hers is an American telehealth company that provides personalized healthcare products and services for mental health, dermatology, sexual wellness, and primary care through a direct-to-consumer platform. (Photo illustration by Cheng Xin/Getty Ima ...

Core Insights - Artificial intelligence (AI) is significantly transforming various industries, particularly healthcare, by enhancing efficiency and improving patient outcomes [1][2]. Group 1: AI in Healthcare - The integration of generative and agentic AI is aiding healthcare professionals in making more accurate diagnoses and reducing administrative burdens, which is crucial given the high burnout rates among physicians, with 93% reporting regular burnout [2]. - AI is positioned to address the supply and demand imbalance in healthcare, especially with an aging population, by bridging the gap between efficiency and personalized care [2]. Group 2: Investment Opportunities - Companies utilizing AI to enhance healthcare outcomes are seen as potential investment opportunities, with specific stocks highlighted for their growth potential [3]. - Hims & Hers Health (HIMS) has experienced a 121% increase in stock value in 2025, attributed to its AI-driven telehealth services that streamline administrative tasks [4][5]. - Tempus AI (TEM) is leveraging AI for precision medicine and oncology, with a 128% stock increase in 2025, and is recognized for its contributions to drug discovery for major pharmaceutical companies [8][10][11]. - Boston Scientific (BSX) is using AI to improve medical device performance and has received FDA approval for a new treatment system, contributing to a 17% stock increase in 2025 [12][14].

Hims & Hers Health, Inc. (NYSE: HIMS ) stock has been on quite a bullish run. It has managed uncertainties well and was able to overcome the fallout of a partnership with Novo Nordisk (I’m a retired Wall Street PM specializing in TMT; since kickstarting my career, I’ve spent over two decades in the market navigating the technology landscape, focusing on risk mitigation through the dot com bubble, credit default of ‘08, and, more recently, with the AI boom. In one word, what I’d like my service to revolve ar ...

Hims & Hers Health, Inc. (NYSE: HIMS ) stock has been on quite a bullish run. It has managed uncertainties well and was able to overcome the fallout of a partnership with Novo Nordisk (I’m a retired Wall Street PM specializing in TMT; since kickstarting my career, I’ve spent over two decades in the market navigating the technology landscape, focusing on risk mitigation through the dot com bubble, credit default of ‘08, and, more recently, with the AI boom. In one word, what I’d like my service to revolve ar ...

YieldMax ETFs grew its expanding lineup of income-oriented funds on Tuesday with the introduction of the YieldMax HIMS Option Income Strategy ETF (NYSE: HIYY). The new fund aims to provide current income by utilizing options-based strategies related to Hims & Hers Health Inc (NYSE: HIMS), a prominent consumer health and wellness business.HIMS stock is showing exceptional strength. See if it is worth your attention here.Unlike other equity ETFs, HIYY does not actually invest in Hims & Hers shares. Instead, t ...

Core Insights - Virtual healthcare and physician-focused digital platforms are transforming U.S. healthcare delivery, with Hims & Hers Health, Inc. and Doximity, Inc. leading the charge [1][2] - Hims & Hers focuses on consumer access and affordability, while Doximity leverages its physician network and enterprise solutions [2] Stock Performance & Valuation - Hims & Hers has increased by 208.8% over the past year, outperforming Doximity's 73.4% gain, although Doximity has outperformed Hims & Hers in the last three months with a 21.8% increase compared to Hims' 11.1% [3][6] - Hims & Hers has a forward price-to-sales (P/S) ratio of 4.6, while Doximity's is at 20.9, both above their respective three-year medians [5] - Hims & Hers has a Zacks Style Score with a Growth Score of A, while Doximity has a Growth Score of B [5] Growth Drivers for Hims & Hers - Hims & Hers is diversifying its offerings into areas like weight loss and chronic conditions, with the rollout of generic semaglutide presenting a significant opportunity [7] - The company is expanding internationally, with plans to enter Canada in 2026 and the acquisition of ZAVA enhancing its European presence [7] - Hims & Hers is investing in AI to improve diagnostics and treatment personalization, aiming for a technology-driven healthcare platform [8] Growth Drivers for Doximity - Doximity has over 80% of U.S. physicians active on its platform, with high engagement levels and a sticky ecosystem that supports recurring revenue growth [10] - The launch of Doximity Scribe, which automates clinical note-taking, has seen strong adoption, with over 75% of users returning weekly [11] - Doximity's growth is supported by strong adoption among pharmaceutical and health system clients, contributing to broad-based revenue growth [12] Earnings Projections - The Zacks Consensus Estimate for Hims & Hers suggests a 122.2% improvement in earnings per share (EPS) from 2024 to 2025 [15] - Doximity's fiscal 2026 EPS is projected to improve by 6.3% from fiscal 2025 [17] Price Targets - The average price target for Hims & Hers is $48.67, indicating a potential decline of 11.3% from the last close [20] - The average price target for Doximity is $68.83, suggesting a potential increase of 7.5% from the last close [23] Investment Considerations - Hims & Hers is viewed as a more stable investment opportunity with strong profitability and user engagement, while Doximity is rapidly expanding but may be trading at a higher valuation [24][25] - Both companies are ranked 3 (Hold) by Zacks, but Hims & Hers is considered to have a more capital-efficient model and better growth prospects [24][25]

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by certain officers and directors of Hims & Hers Health, Inc. related to misleading statements and actions that may have jeopardized shareholder interests [1]. Group 1: Allegations Against Hims & Hers Health, Inc. - Insiders at Hims & Hers Health allegedly misrepresented or failed to disclose involvement in the deceptive promotion and sale of illegitimate versions of Wegovy, which posed risks to patient safety [1]. - There is a substantial risk that the company's collaboration with Novo Nordisk could be terminated due to these actions [1]. - Positive statements regarding the company's business, operations, and prospects were claimed to be materially misleading and lacked a reasonable basis [1].

Core Viewpoint - Hims & Hers Health, Inc. is experiencing significant growth in earnings and revenue, with upcoming earnings expected to show substantial year-over-year increases, despite a recent decline in stock price [2][3]. Financial Performance - The stock of Hims & Hers Health, Inc. decreased by 2.95% to $56.00, underperforming the S&P 500's daily loss of 0.55% [1] - Over the past month, the stock has risen by 34.22%, contrasting with a 0.2% loss in the Medical sector and a 3.64% gain in the S&P 500 [1] - The company is projected to report an EPS of $0.09, reflecting a 50% growth compared to the same quarter last year, with anticipated revenue of $581.61 million, indicating a 44.84% increase year-over-year [2] - For the entire fiscal year, earnings are expected to be $0.6 per share and revenue is projected at $2.35 billion, representing increases of 122.22% and 58.91% respectively from the previous year [3] Analyst Sentiment - Recent revisions to analyst forecasts for Hims & Hers Health, Inc. are crucial, as positive estimate revisions indicate analyst optimism regarding the company's business and profitability [4] - The Zacks Rank system, which evaluates estimate changes, currently assigns Hims & Hers Health, Inc. a rank of 3 (Hold), with the consensus EPS estimate remaining unchanged over the past month [6] Valuation Metrics - Hims & Hers Health, Inc. has a Forward P/E ratio of 96.47, which is significantly higher than the industry average Forward P/E of 39.85 [7] - The company has a PEG ratio of 3.9, compared to the Medical Info Systems industry's average PEG ratio of 3.35, indicating a premium valuation relative to growth expectations [8] Industry Context - The Medical Info Systems industry, which includes Hims & Hers Health, Inc., holds a Zacks Industry Rank of 70, placing it in the top 29% of over 250 industries [8][9] - The Zacks Industry Rank suggests that the top 50% rated industries outperform the bottom half by a factor of 2 to 1, highlighting the potential for growth within this sector [9]